1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESC: Alnylam’s Aim For First-Line Amvuttra Use Looks Dicey

 
• By Elizabeth Cairns

The full pivotal data in ATTR cardiomyopathy suggest the transthyretin silencer could find a niche as an add-on to Pfizer’s established drug Vyndamax.    

Heart shaped pills on a black background
• Source: Alamy

Following their toplining in June, the keenly awaited full results of the pivotal HELIOS-B trial of Alnylam Pharmaceuticals Inc.’s Amvuttra in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have turned out to be something of a disappointment.

Key Takeaways
  • Full data from the HELIOS-B trial of Alnylam’s Amvuttra in transthyretin amyloidosis with cardiomyopathy look weaker than data on Pfizer’s Vyndamax and BridgeBio’s acoramidis.

The data, presented at the annual congress of the European Society of Cardiology in London on 30 August, suggest that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.